China offers a scale that few healthcare systems can match. But success in China’s medtech market requires a long-term commitment, deep understanding of regulatory pathways, and strong relationship capital (guanxi).
China offers a scale that few healthcare systems can match. But success in China’s medtech market requires a long-term commitment, deep understanding of regulatory pathways, and strong relationship capital (guanxi).
The Netherlands is often underestimated. But the country combines a dense innovation ecosystem, a highly organised healthcare system and a position as one of Europe's most demanding proving grounds for evidence.
The United States represents more than 45% of the global medtech market, worth an estimated US$190 billion annually, and remains one of the most influential healthcare markets shaping global trends in investment, regulation and commercialisation.
India is emerging as one of the most important long-term growth markets in medtech. With more than 1.4 billion people, a rapidly growing economy and increasing political focus on healthcare access, the opportunity is significant.
Internationalisation in medtech is often described as expansion. In reality, it’s a sequence of strategic choices that shape the entire trajectory of a company. Where you enter first does not simply unlock growth, it defines what kind of company you become.
Companies that succeed in the long term see regulatory affairs as an active part of their communication and market strategy. When you clearly communicate and show how you work, you build trust. And trust sells.
Global regulatory strategy is not about doing everything at once. It's about designing the product, documentation and structure to work for multiple markets from the start.
When the team understands why the structure exists, and how it helps them make better decisions, regulation becomes a support for innovation, not an obstacle.
Regulatory readiness har blivit en avgörande indikator för investerare på bolagets mognad, riskprofil och kommersiella potential. Ett bolag utan regulatorisk plan är en osäker investering.
De flesta entreprenörer ser CE-märkningen som ett hinder man måste ta sig över. Men de bolag som lyckas allra bäst, ser det som en del av sin affärsstrategi. Att bygga regulatorik tidigt är att bygga för stabilitet och skalning.
